Trial Profile
Phase I, Multicenter, Cohort Dose Escalation Trial to Determine the Safety, Tolerance, and Maximum Tolerated Dose of DCR-MYC, a Lipid Nanoparticle (LNP)-Formulated Small Inhibitory RNA (siRNA) Oligonucleotide Targeting MYC, in Patients With Refractory Locally Advanced or Metastatic Solid Tumor Malignancies, Multiple Myeloma, or Lymphoma
Status:
Discontinued
Phase of Trial:
Phase I
Latest Information Update: 03 May 2023
Price :
$35
*
At a glance
- Drugs DCR MYC (Primary)
- Indications Lymphoma; Multiple myeloma; Neuroendocrine tumours; Non-Hodgkin's lymphoma; Pancreatic cancer; Solid tumours
- Focus Adverse reactions; First in man; Proof of concept
- Sponsors Dicerna Pharmaceuticals
- 03 Aug 2017 Status changed from active, no longer recruiting to discontinued as per the sponsor decision
- 25 Jul 2017 Planned End Date changed from 1 Dec 2016 to 31 Aug 2017.
- 25 Jul 2017 Planned primary completion date changed from 1 Dec 2016 to 31 Aug 2017.